The Obama administration finalized a rule that would fine drug makers for overcharging hospitals, clinics, and other providers for medicines that are purchased under the federal government’s 340B drug discount program.
Under the rule, which was issued on Wednesday by the US Health Resources and Service Administration, drug makers could be fined up to $5,000 for each instance in which they “knowingly and intentionally” overcharge for their medicines. The companies must also reimburse providers for medicines that were purchased.
About the Author Reprints
